Liang Ping, Dong Baowei, Yu Xiaoling, Yu Dejiang, Wang Yang, Feng Lei, Xiao Qiujin
Department of Ultrasound, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing 100853, China.
Radiology. 2005 Apr;235(1):299-307. doi: 10.1148/radiol.2351031944. Epub 2005 Feb 24.
To determine the long-term survival and prognostic factors in patients with hepatocellular carcinoma treated with percutaneous microwave ablation.
Institutional review board approval and informed consent were obtained. A database of cases of hepatocellular carcinoma in 288 patients (259 men, 29 women; mean age, 54.8 years +/- 11.4 [standard deviation]; age range, 25-82 years) with 477 histologically proved lesions who underwent percutaneous microwave coagulation therapy between May 1994 and October 2002 was retrospectively analyzed. Prognostic factors for survival were evaluated by means of univariate and multivariate analyses.
The mean follow-up period after microwave ablation was 31.41 months +/- 20.43 (range, 5-106 months). The 1-, 2-, 3-, 4-, and 5-year cumulative survival rates among all 288 patients were 93%, 82%, 72%, 63%, and 51%, respectively. Ninety-three patients (32%) died. Local recurrence or new tumors occurred in 100 patients (35%). Age (P = .836), sex (P = .073), preablation serum alpha-fetoprotein level (P = .136), and preablation treatment (P = .256) were not related to prognosis, while tumor number (P = .004), tumor size (P < .001), Child-Pugh classification (P = .003), tumor differentiation (P = .026), and local recurrence or presence of new tumors (P = .004) significantly affected survival at univariate analysis. At multivariate analysis, only tumor size (P < .001), number of nodules (P = .005), and Child-Pugh classification (P = .01) each had a significant effect on survival.
With use of microwave ablation, there is a high probability of long-term survival of patients with a single lesion of 4.0 cm or less in maximum diameter and Child-Pugh class A cirrhosis.
确定经皮微波消融治疗肝细胞癌患者的长期生存率及预后因素。
获得机构审查委员会批准并取得知情同意。回顾性分析了1994年5月至2002年10月期间288例肝细胞癌患者(259例男性,29例女性;平均年龄54.8岁±11.4[标准差];年龄范围25 - 82岁)的数据库,这些患者有477个经组织学证实的病灶,均接受了经皮微波凝固治疗。通过单因素和多因素分析评估生存的预后因素。
微波消融后的平均随访期为31.41个月±20.43(范围5 - 106个月)。288例患者中1年、2年、3年、4年和5年的累积生存率分别为93%、82%、72%、63%和51%。93例患者(32%)死亡。100例患者(35%)出现局部复发或新肿瘤。年龄(P = 0.836)、性别(P = 0.073)、消融前血清甲胎蛋白水平(P = 0.136)和消融前治疗(P = 0.256)与预后无关,而肿瘤数量(P = 0.004)、肿瘤大小(P < 0.001)、Child-Pugh分级(P = 0.003)、肿瘤分化(P = 0.026)以及局部复发或新肿瘤的存在(P = 0.004)在单因素分析中对生存有显著影响。在多因素分析中,只有肿瘤大小(P < 0.001)、结节数量(P = 0.005)和Child-Pugh分级(P = 0.01)对生存有显著影响。
对于最大直径4.0 cm或更小的单个病灶且Child-Pugh A级肝硬化的患者,使用微波消融治疗有较高的长期生存概率。